DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 21-299/S-007

Synthon Pharmaceuticals Ltd.
Attention: Susan W. Harts, RN, RAC
Vice President of Regulatory Affairs
6330 Quadrangle Drive, Suite 305
Chapel Hill, NC 27514

Dear Ms. Harts:

We acknowledge receipt of your supplemental new drug application dated May 21, received May 24, 2004, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for Pexeva (paroxetine mesylate) 10 mg, 20 mg, 30 mg, and 40 mg Tablets.

Reference is also made to Agency communications dated March 26, and April 20, 2004, requesting revisions to product labeling in order to incorporate class labeling revisions.

The above supplemental application, submitted under "Changes Being Effected", provide for the following revisions to product labeling as requested in the above Agency communications:

1. The addition of a new subsection under **WARNINGS** entitled **Clinical Worsening and Suicide Risk**.
2. Revisions to the **PRECAUTIONS-Information for Patients** section regarding clinical worsening.
3. Deletion of the section in **PRECAUTIONS-General** entitled "Suicide".
4. Add a reference to the **WARNINGS** section at the end of the **PRECAUTIONS- Pediatric Use** section, i.e., (see **WARNINGS-Clinical Worsening and Suicide Risk**).
5. Revisions to the subsection under **PRECAUTIONS-General-Discontinuation of Treatment with Paroxetine**.
6. Revisions to the subsection under **PRECAUTIONS-General-Abnormal Bleeding**.
7. The addition of an abnormal bleeding paragraph in the **PRECAUTIONS-Information for Patients** section.
8. The addition of a new subsection entitled **Drugs That Interfere With Hemostasis (Non-selective NSAIDs, Aspirin, Warfarin, etc.)** in the **PRECAUTIONS-Drug Interactions** section.
9. The addition of a new subsection entitled **Nonteratogenic Effects** in the **PRECAUTIONS-Pregnancy** section.
10. The addition of a new subsection entitled **Treatment of Pregnant Women During the Third Trimester** in the **DOSAGE AND ADMINISTRATION-Special Populations** section.

We have completed our review of this supplemental application, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the submitted final printed labeling (package insert submitted May 21, 2004), which incorporates all of the revisions made in the above supplement. Accordingly, this supplemental application is approved effective on the date of this letter.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Mr. Paul David, R.Ph., Senior Regulatory Project Manager, at (301) 594-5530.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Russell Katz

8/30/04 08:36:27 AM